Delivery Order SPE2DB24D2205-SPE2DB25FEAHN

Award Date 3/31/25
Potential Completion Date 4/1/25
Potential Value $9.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,461.28 delivery order contract is for the supply of 4,567,916,245 units of the prescription medication Carvedilol ER 10 mg capsules. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 16, 2025. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,066.14 firm fixed-price delivery order is for the supply of Carvedilol ER 10 mg capsules, a cardiovascular medication. The contract has a completion date of November 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,894.08 firm fixed price delivery order is for the supply of Carvedilol ER 20 mg capsules. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military...
This federal contract award from the Defense Logistics Agency (DLA) is a delivery order worth $2,709.99 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for 4,562,968,106 units of the drug Carvedilol ER 20 mg capsules, with a completion date of December 4, 2023. The contract has a firm fixed price pricing type and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Carvedilol ER 20 mg capsules. The $7,054.08 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support military treatment programs and facilities...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Carvedilol ER 40 mg capsules. The $10,734.40 firm fixed-price contract has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Carvedilol ER 10 mg capsules. The contract has a ceiling value of $4,346.65 and an ultimate completion date of January 27, 2025. It is a firm fixed-price delivery order contract without any set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award, valued at $2,155.95, is for the delivery of Carvedilol ER 20 mg capsules. The contract is a Firm Fixed Price Delivery Order with a period of performance through January 21, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,297.49 firm fixed-price delivery order is for the supply of Carvedilol ER 40 mg capsules. The contract has an ultimate completion date of November 1, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of 4566599978 units of the drug carvedilol ER 20 mg capsules. The $21,226.09 firm fixed-price contract was awarded on December 3, 2024 by the Defense Logistics Agency (DLA) and has an ultimate completion date of December 4, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FEAHN
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,567,750,853 units of the drug carvedilol ER 20 mg capsules. The contract is a Firm Fixed Price Delivery Order valued at $9,155.47, with a period of performance through April 1, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as the primary vehicle for this specific order. The contract does not have a set-aside designation, indicating open competition. This award supports the DLA's role in supplying essential pharmaceutical products to military treatment facilities, veterans' healthcare programs, and other federal medical institutions.

Generated 6/30/25, 11:00 AM